Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Abstract Text:

Anthony J Bella,Ling X Deyoung,Mussa Al-Numi,Gerald B Brock,

OBJECTIVES: Although the discovery of phosphodiesterases (PDEs) was made soon after the identification of cyclic adenosine monophosphate nearly half a century ago, their true importance in medicine has taken many decades to be realised. The recognition of the important role PDE enzymes play and the impact of altering intracellular cyclic nucleotide levels became significant for most urologists and clinicians in the early 1990s with the discovery of sildenafil, a PDE5 inhibitor (PDE5-I). Once approved around the world, on-demand use of PDE5-Is became the gold standard. Recently, the potential beneficial effects of PDE5-Is on the pulmonary, vascular, and other systems has led to examination of alternative dosing regimens. In this review, we have synthesised the available published peer-reviewed literature to provide a critical contemporary view of evolving indications for PDE5-Is and how alternative dosing regimens may impact on sexual and other functions. METHODS: MEDLINE search of all peer-reviewed English literature for the period 1990-2007. RESULTS: The plethora of articles detailing potential uses of PDE5-I in multiple fields of medicine was uncovered. Use of alternative dosing regimens shows great promise across a number of clinical indications, including post-radical retropubic prostatectomy, pulmonary hypertension, endothelial dysfunction, and salvage of on-demand PDE5-I nonresponders. CONCLUSIONS: Use of PDE5-I on a daily basis may evolve into a major form of drug administration both for men with erectile dysfunction and for those with a myriad of other conditions shown to benefit from this approach.

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Publishing Authors By Initials

AJ Bella,LX Deyoung,M Al-Numi,GB Brock,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Journal Published:

PUBLICATION TYPE: Review

Journal: European urology

VOLUME: 52

Page Numbers: 990-1005

Journal Abbreviation: Eur. Urol.

ISSN: 0302-2838

DAY: 23

MONTH: 07

YEAR: 2007

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Information

Number of References: 150

LANGUAGE: eng

NlmUniqueID: 7512719

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.

AFFILIATION: Department of Surgery, Division of Urology, University of Ottawa, Ottawa, Canada.

Country: Switzerland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Eur Urol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications Related Publications

• A case series of HIV-positive patients with malignant melanoma.
• A general methodology for the synthesis of transition metal pnictide nanoparticles from pnictate precursors and its application to iron-phosphorus phases.
• An HIV-associated mediastinal germ cell tumour complicated by acute myeloid leukaemia.
• An artificial mitochondrial tail signal/anchor sequence confirms a requirement for moderate hydrophobicity for targeting.
• An improved system for the generation and analysis of mutant proteins containing unnatural amino acids in Saccharomyces cerevisiae.
• An unexpected co-crystal with a variable degree of order: 1:1 rac-1,2-cyclohexanediol/triphenylphosphine oxide.
• Congenital cyanotic heart disease.
• Contact surface and material nonlinearity modeling of human lungs.
• Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
• Drainage, streptomycin and tuberculosis.
• Evaluation of hunter-harvested white-tailed deer for evidence of bovine viral diarrhea virus infection in Alabama.
• Expression of 5-lipoxygenase in specialized epithelial cells of nasopharyngeal-associated lymphoid tissue.
• First stage approximation of the exstrophic bladder in patients with cloacal exstrophy--should this be the initial surgical approach in all patients?
• HOW THE CONFEDERATE ARMY WAS VACCINATED.
• Leukotrienes: mediators that have been typecast as villains.
• Malnutrition in South Africa.
• Morbus coeruleus; a study of 50 cases after the Blalock-Taussig operation.
• Particle-rod hybrids: growth of arachidic acid molecular rods from capped cadmium selenide nanoparticles.
• Potential mRNA degradation targets of hsa-miR-200c, identified using informatics and qRT-PCR.
• Surgical outcomes and patient satisfaction after dermal, pericardial, and small intestinal submucosal grafting for Peyronie's disease.
• Synthesis of MnP nanocrystals by treatment of metal carbonyl complexes with phosphines: a new, versatile route to nanoscale transition metal phosphides.
• The activity of lipopeptide TLR2 agonists critically depends on the presence of solubilizers.
• The impact of a fellowship on resident training in an academic pediatric urology practice.
• The role of patients' expectations and goals in the behavioral and pharmacological treatment of obesity.
• The surgery of pulmonary stenosis.
• The surgery of the heart.
• Transcriptional interference: an unexpected layer of complexity in gene regulation.
• [Not Available.]
• [Not Available.]
• miRNA: the new gene silencer.